Forbes March 17, 2025
For those who are overweight or obese, medications known as glucagon-like peptide-1 agonists, or GLP-1s, have become very popular as weight loss treatments. Taken in accordance with instructions on the label and an appropriate diet and exercise regimen, GLP-1s are effective at lowering a person’s weight. Given the various co-morbidities associated with obesity, including diabetes and cardiovascular disease, intuitively, it would seem that GLP-1 use for weight loss would be cost-effective and possibly reduce overall medical costs despite the increase in prescription drug spending. But thus far, the data don’t show this.
According to an analysis published last week in the Journal of the American Medical Association Health Forum, improved health outcomes notwithstanding, weight loss medications were not found to...
Today's Sponsors
Today's Sponsor